biology

Meningococcal vaccine

Meningococcal vaccine is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Meningococcal vaccine rather than just read about it. In short: Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y.

Key takeaways

Meningococcal vaccine belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Meningococcal vaccine to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Meningococcal vaccine from memory before moving on to harder problems.

Reference excerpt

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. The World Health Organization recommends that countries with a moderate or high rate of disease or with frequent outbreaks should routinely vaccinate. In countries with a low risk of disease, they recommend that high-risk groups should be immunized. In the African meningitis belt efforts to immunize all people between the ages of one and thirty with the meningococcal A conjugate vaccine are ongoing. In Canada and the United States, vaccines against four types of meningococcus (A, C, W, and Y) are recommended routinely for teenagers and others who are at high risk. Saudi Arabia requires vaccination with the quadrivalent vaccine for international travellers to Mecca for Hajj. Meningococcal vaccines are generally safe. Some people develop pain and redness at the injection site. Use in pregnancy appears to be safe. Severe allergic reactions occur in less than one in a million doses. The first meningococcal vaccine became available in the 1970s. It is on the World Health Organization's List of Essential Medicines. Inspired by the response to the 1997 outbreak in Nigeria, the WHO, Médecins Sans Frontières, and other groups created the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control, which manages global response strategy. ICGs have since been created for other epidemic diseases.

Types Neisseria meningitidis has 13 clinically significant serogroups, classified according to the antigenic structure of their polysaccharide capsule. Six serogroups, A, B, C, Y, W-135, and X, are responsible for virtually all cases in humans. Serogroup B is a major cause of meningococcal disease in younger children and adolescents.

Pentavalent (serogroups A, B, C, W, and Y) There are two pentavalent vaccines available in the United States targeting serogroups A, B, C, W, and Y:

Penbraya was approved for use in the United States in October 2023. It combines the vaccines Trumenba and Nimenrix. Penbraya was authorized for medical use in the European Union in November 2024. It is approved for use in individuals 10 through 25 years of age. Penmenvy was approved for use in the United States in February 2025. Penmenvy is approved for use in people aged 10 through 25 years of age.

Pentavalent (serogroups A, C, W, X, and Y) (MenFive) There is one pentavalent vaccine available targeting serogroups A, C, W, X, and Y:

MenFive: Approved in several countries, and WHO prequalified. It is approved for use in individuals aged 9 months to 85 years against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, Y, W, and X. It is a freeze-dried conjugate vaccine, recommended as a single intramuscular dose, and is available as 1-dose and 5-dose vials.

Quadrivalent (serogroups A, C, W-135, and Y)

There are three quadrivalent vaccines available in the United States targeting serogroups A, C, W-135, and Y:

three conjugate vaccines (MCV-4), Menactra, Menveo, and Menquadfi. The pure polysaccharide vaccine Menomune, MPSV4, was discontinued in the United States in 2017. Menveo and Menquadfi are approved for medical use in the European Union.

Menactra and Menveo The first meningococcal conjugate vaccine (MCV-4), Menactra, was licensed in the US in 2005, by Sanofi Pasteur; Menveo was licensed in 2010, by Novartis. Both MCV-4 vaccines are approved by the Food and Drug Administration (FDA) for people 2 through 55 years of age. Menactra received FDA approval for use in children as young as 9 months in April 2011, while Menveo received FDA approval for use in children as young as two months in August 2013. The Centers for Disease Control and Prevention (CDC) has not made recommendations for or against its use in children less than two years. In November 2024, the European Commission (EC) approved Menveo to protect individuals aged two years and older against invasive meningococcal disease.

Menquadfi

Menquadfi, manufactured by Sanofi Pasteur, was approved by the US Food and Drug Administration in April 2020, for use in individuals two years of age and older.

Menomune Meningococcal polysaccharide vaccine (MPSV-4), Menomune, has been available since the 1970s. It may be used if MCV-4 is not available, and is the only meningococcal vaccine licensed for people older than 55. Information about who should receive the meningococcal vaccine is available from the CDC.

Nimenrix

Nimenrix (developed by GlaxoSmithKline and later acquired by Pfizer), is a quadrivalent conjugate vaccine against serogroups A, C, W-135, and Y. In April 2012 Nimenrix was approved as the first quadrivalent vaccine against invasive meningococcal disease to be administered as a single dose in those over the age of one year, by the European Medicines Agency. In 2016, they approved the vaccine in infants six weeks of age and older, and it has been approved in other countries including Canada and Australia, among others. It is not licensed in the United States.

Mencevax Mencevax (GlaxoSmithKline) and NmVac4-A/C/Y/W-135 (JN-International Medical Corporation) are used worldwide but have not been licensed in the United States.

Limitations The duration of immunity mediated by Menomune (MPSV-4) is three years or less in children aged under five because it does not generate memory T cells. Attempting to overcome this problem by repeated immunization results in a diminished, not increased, antibody response, so boosters are not recommended with this vaccine. As with all polysaccharide vaccines, Menomune does not produce mucosal immunity, so people can still become colonised with virulent strains of meningococcus, and no herd immunity can develop. For this reason, Menomune is suitable for travellers requiring short-term protection, but not for national public health prevention programs. Menveo and Menactra contain the same antigens as Menomune, but the antigens are conjugated to a diphtheria toxoid polysaccharide-protein complex, resulting in anticipated enhanced duration of protection, increased immunity with booster vaccinations, and effective herd immunity.

… excerpt ends here. Continue reading the full article.

Illustrations

Worked examples

Example 1 — a first encounter with Meningococcal vaccine

Start with the simplest possible case. Write down what Meningococcal vaccine claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Meningococcal vaccine before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Meningococcal vaccine ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Meningococcal vaccine

In research: Meningococcal vaccine appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Meningococcal vaccine in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Meningococcal vaccine is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs developed by GSK plc, Drugs developed by Novartis, Meningococcal vaccines, so understanding it makes those chapters shorter.
In everyday life: Look for Meningococcal vaccine outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Meningococcal vaccine” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Meningococcal vaccine in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Meningococcal vaccine means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Meningococcal vaccine out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Meningococcal vaccine in simple terms?

Why does Meningococcal vaccine matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Meningococcal vaccine?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Meningococcal vaccine.